{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2021)
Source URL:
First approved in 2017
Source:
AtopiCream HC by VetriMax Veterinary Products, LLC
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 350
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 350
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
STRAWFIELD PETS ANTISEPTICPLUS CHLORHEXIDINE by NEXTMUNE AB
(2023)
Source URL:
First approved in 2017
Source:
Pet MD Chlorhexidine Wipes XL by Pet MD Brands, LLC
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2018)
Source URL:
First approved in 2017
Source:
BLA125614
Source URL:
Class:
MIXTURE
QS-21 is a purified soapbark tree (Quillaja saponaria) extract that enhances the ability of the immune system to respond to vaccine antigens. QS-21 is a promising adjuvant candidate for use in humans due to the ease of purification, its improved safety profile, and its ability to enhance cellular and humoral immunogenicity. The mechanism of action of QS-21 was speculated to be similar to QA, forming complexes with cholesterol that intercalate into the cell membrane lipids. This intercalation creates pores in the membrane to accelerate the uptake of a co-delivered antigen by the antigen presenting cells. Multiple clinical trials using QS-21 as an adjuvant, demonstrated satisfactory safety profiles and enhanced immunogenicity in immunocompromised volunteers
Status:
Possibly Marketed Outside US
Source:
NCT04590521: Phase 4 Interventional Completed HPV Infection
(2022)
Source URL:
First approved in 2017
Source:
BLA125614
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M032
(2017)
Source URL:
First approved in 2017
Source:
BEST FACE FORWARD by ASPIRE BRANDS INC
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2017)
Source URL:
First approved in 2017
Source:
505G(a)(3)
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M019
(2024)
Source URL:
First approved in 2017
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE